The Role of the CTLA4 Blockade in the Treatment of Malignant Melanoma

ISSN： 0735-7907

Source： Cancer Investigation, Vol.25, Iss.7, 2007-10, pp. : 613-631

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study

By Queirolo P.

Cancer Investigation, Vol. 31, Iss. 5, 2013-06 ,pp. : 336-345

Informa Healthcare

Access to resources Recommend Favorite

Anti-CTLA4 Monoclonal Antibody Ipilimumab in the Treatment of Metastatic Melanoma: Recent Findings

Recent Patents on Anti-Cancer Drug Discovery, Vol. 3, Iss. 2, 2008-06 ,pp. : 105-113

Bentham Science Publishers

Access to resources Recommend Favorite

CTLA‐4 blockade with ipilimumab: biology, safety, efficacy, and future considerations

Cancer Medicine, Vol. 4, Iss. 5, 2015-05 ,pp. : 661-672

John Wiley & Sons Inc

Access to resources Recommend Favorite

The role interferon-alpha in malignant melanoma remains to be defined

By Eggermont A.M.M.

European Journal of Cancer, Vol. 37, Iss. 17, 2001-01 ,pp. : 2147-2153

Elsevier

Access to resources Recommend Favorite

Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine

By Seeber A. Binder M. Steiner A. Wolff K. Pehamberger H.

European Journal of Cancer, Vol. 34, Iss. 13, 1998-12 ,pp. : 2129-2131

Elsevier

Access to resources Recommend Favorite